Minnesota Senate Bill SF2959

Minnesota 2025-2026 Regular Session

• Introduced: 3/24/25
• Refer: 3/24/25

Caption

Manufacturers interfering with access to 340B drugs prohibition extension

Impact

If passed, SF2959 would maintain and enhance access to vital prescription drugs for individuals relying on 340B pricing. This extension is crucial for various healthcare providers, including federally qualified health centers and disproportionate share hospitals, which utilize the savings from the 340B program to support community health services. The implications of this bill could significantly affect the operational frameworks of these providers by securing uninterrupted access to affordable medications, which are essential for treating chronic conditions among vulnerable groups.

Summary

SF2959 is a legislative bill introduced in Minnesota aimed at extending a prohibition on drug manufacturers interfering with access to 340B drugs. The bill seeks to repeal a specific section of Minnesota Statutes, effectively removing a provision that may limit access to essential medications for low-income and underserved populations through the 340B Drug Pricing Program. This program allows healthcare providers serving these populations to purchase outpatient drugs at significantly reduced prices, thereby improving access and affordability.

Contention

The discourse surrounding SF2959 may reflect broader tensions between pharmacy benefit managers, pharmaceutical manufacturers, and healthcare providers. While proponents of the bill advocate for the necessity of access to affordable medications, opposition may arise from those who argue that extending the prohibition could impact the pricing strategies of drug manufacturers and their ability to operate sustainably. This clash illustrates the ongoing debate concerning drug pricing, access to healthcare, and the balance of interests between the pharmaceutical industry and public health objectives.